TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth: A CBPR RCT
Brief Summary: The goal of this project is to evaluate the effectiveness of a family-based tobacco use prevention intervention directed at immigrant Latino parents of middle school aged youth as delivered in partnership with seven community organizations. The primary outcomes of the study are youth susceptibility to tobacco use, and changes in parenting practices among the parents of the youth. The planning, initiation, and delivery of the intervention will occur in collaboration with community organizations that have identified this project as important to the families they serve. Though the collaboratively designed training curriculum has been successfully tested and a study design for the current project established, a substantive development period for this project will allow the research team and collaborating organizations to consider key aspects of design and delivery.


Options:
A: Arm Label: Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Family-Skills Training | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Family-Skills Training | Intervention Type: BEHAVIORAL; Name: Family-Skills Training; Assigned to Arm(s): Control Group, Intervention Group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: brief intervention (cognitive-behavioral therapy) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: brief intervention (cognitive-behavioral therapy) | Intervention Type: BEHAVIORAL; Name: brief intervention (cognitive-behavioral therapy); Assigned to Arm(s): 1, 2
C: Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Communities That Care Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Communities That Care | Intervention Type: BEHAVIORAL; Name: Communities That Care; Assigned to Arm(s): Communities That Care Intervention
D: Arm Label: Örebro prevention program; Type: EXPERIMENTAL; Interventions: Behavioral: Örebro prevention program | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Business as usual | Intervention Type: BEHAVIORAL; Name: Örebro prevention program; Assigned to Arm(s): Örebro prevention program | Intervention Type: BEHAVIORAL; Name: Business as usual; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma
Brief Summary: The purpose of this study is to explore the efficacy of bevacizumab combined with radiotherapy compared with radiotherapy alone in the treatment of newly diagnosed glioblastoma in the elderly.

* Trial with medicinal product


Options:
A: Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
B: Arm Label: Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiation therapy | Arm Label: Radiotherapy plus Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Radiotherapy plus Bevacizumab | Intervention Type: RADIATION; Name: Radiation therapy; Assigned to Arm(s): Radiotherapy
C: Arm Label: Cediranib & Gefitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: cediranib maleate, Drug: gefitinib | Arm Label: Cediranbib & placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: cediranib maleate, Drug: Placebo | Intervention Type: DRUG; Name: cediranib maleate; Assigned to Arm(s): Cediranbib & placebo, Cediranib & Gefitinib | Intervention Type: DRUG; Name: gefitinib; Assigned to Arm(s): Cediranib & Gefitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cediranbib & placebo
D: Arm Label: Arm 1 - Short Course Radiotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Radiotherapy | Arm Label: Arm 2 - Standard Course Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Arm 1 - Short Course Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Arm 2 - Standard Course Radiotherapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma
Brief Summary: The purpose of this study is to explore the efficacy of bevacizumab combined with radiotherapy compared with radiotherapy alone in the treatment of newly diagnosed glioblastoma in the elderly.

* Trial with medicinal product


Options:
A: Arm Label: Single arm; Type: EXPERIMENTAL; Interventions: Biological: CAN-2409, Drug: Valacyclovir, Drug: Temozolomide, Radiation: Radiation therapy | Intervention Type: BIOLOGICAL; Name: CAN-2409; Assigned to Arm(s): Single arm | Intervention Type: DRUG; Name: Valacyclovir; Assigned to Arm(s): Single arm | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Single arm | Intervention Type: RADIATION; Name: Radiation therapy; Assigned to Arm(s): Single arm
B: Arm Label: Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiation therapy | Arm Label: Radiotherapy plus Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Radiotherapy plus Bevacizumab | Intervention Type: RADIATION; Name: Radiation therapy; Assigned to Arm(s): Radiotherapy
C: Arm Label: Observation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Radiation therapy; Type: EXPERIMENTAL; Interventions: Radiation: radiation therapy | Arm Label: Radiation plus PCV chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: lomustine, Drug: procarbazine hydrochloride, Drug: vincristine sulfate, Radiation: radiation therapy | Intervention Type: DRUG; Name: lomustine; Assigned to Arm(s): Radiation plus PCV chemotherapy | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): Radiation plus PCV chemotherapy | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Radiation plus PCV chemotherapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Radiation plus PCV chemotherapy, Radiation therapy
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Radiation: Stereotactic Conformal radiotherapy | Arm Label: 2; Type: OTHER; Interventions: Radiation: Conventional radiotherapy | Intervention Type: RADIATION; Name: Stereotactic Conformal radiotherapy; Assigned to Arm(s): 1 | Intervention Type: RADIATION; Name: Conventional radiotherapy; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D for Sickle-cell Respiratory Complications
Brief Summary: This study aims to answer the question whether oral vitamin D supplementation can decrease lung complications in children and adolescents with sickle cell disease. Lung complications are the leading causes of morbidity and of death in sickle cell disease. Infections and increased inflammation play important roles in the development of the lung problems in sickle cell disease. Emerging evidence shows that vitamin D helps the immune system to fight infection and to control inflammation and could potentially help prevent respiratory complications in patients with sickle cell disease. The investigators hypothesize that oral vitamin D3, 100,000 IU (2.5 mg), given once a month to a group of children and adolescents with sickle cell disease, will reduce the rate of respiratory events (infection, asthma exacerbation and acute chest syndrome) compared to the rate in a group given standard dose oral vitamin D3, 12,000 IU (0.3 mg) given once a month.

Funding Source - U.S. Food \& Drug Administration, Office of Orphan Products Development


Options:
A: Arm Label: Vitamin D3 100,000 IU; Type: EXPERIMENTAL; Interventions: Drug: Experimental: Vitamin D3 100,000 IU | Arm Label: Vitamin D3 12,000 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active Comparator: Vitamin D3 12,000 IU | Intervention Type: DRUG; Name: Experimental: Vitamin D3 100,000 IU; Assigned to Arm(s): Vitamin D3 100,000 IU | Intervention Type: DRUG; Name: Active Comparator: Vitamin D3 12,000 IU; Assigned to Arm(s): Vitamin D3 12,000 IU
B: Arm Label: Ciclesonide + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: Ciclesonide + Vitamin D; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3, Drug: Ciclesonide | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Ciclesonide + Vitamin D | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): Ciclesonide + Vitamin D, Ciclesonide + placebo
C: Arm Label: Vigantol oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol | Arm Label: Miglyol oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Miglyol oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): Vigantol oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Miglyol oil; Assigned to Arm(s): Miglyol oil
D: Arm Label: Intervention Group (IG); Type: EXPERIMENTAL; Interventions: Drug: Calcifediol | Arm Label: Control Group (CG); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Calcifediol; Assigned to Arm(s): Intervention Group (IG) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control Group (CG)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D for Sickle-cell Respiratory Complications
Brief Summary: This study aims to answer the question whether oral vitamin D supplementation can decrease lung complications in children and adolescents with sickle cell disease. Lung complications are the leading causes of morbidity and of death in sickle cell disease. Infections and increased inflammation play important roles in the development of the lung problems in sickle cell disease. Emerging evidence shows that vitamin D helps the immune system to fight infection and to control inflammation and could potentially help prevent respiratory complications in patients with sickle cell disease. The investigators hypothesize that oral vitamin D3, 100,000 IU (2.5 mg), given once a month to a group of children and adolescents with sickle cell disease, will reduce the rate of respiratory events (infection, asthma exacerbation and acute chest syndrome) compared to the rate in a group given standard dose oral vitamin D3, 12,000 IU (0.3 mg) given once a month.

Funding Source - U.S. Food \& Drug Administration, Office of Orphan Products Development


Options:
A: Arm Label: Atopic dermatitis patients: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral vitamin D | Arm Label: Atopic dermatitis patients: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: oral vitamin D; Assigned to Arm(s): Atopic dermatitis patients: Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Atopic dermatitis patients: Placebo
B: Arm Label: Usual care group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: High Dose Group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cholecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): High Dose Group
C: Arm Label: Vitamin D3 100,000 IU; Type: EXPERIMENTAL; Interventions: Drug: Experimental: Vitamin D3 100,000 IU | Arm Label: Vitamin D3 12,000 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active Comparator: Vitamin D3 12,000 IU | Intervention Type: DRUG; Name: Experimental: Vitamin D3 100,000 IU; Assigned to Arm(s): Vitamin D3 100,000 IU | Intervention Type: DRUG; Name: Active Comparator: Vitamin D3 12,000 IU; Assigned to Arm(s): Vitamin D3 12,000 IU
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D, cholecalciferol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D, cholecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D, cholecalciferol; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D, cholecalciferol; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study to Evaluate the Effect of Roflumilast 500 μg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS)
Brief Summary: To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD.


Options:
A: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 25 mcg; Type: EXPERIMENTAL; Interventions: Drug: GSK256066 | Arm Label: 87.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: GSK256066 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GSK256066; Assigned to Arm(s): 25 mcg, 87.5 mcg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Roflumilast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study to Evaluate the Effect of Roflumilast 500 μg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS)
Brief Summary: To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD.


Options:
A: Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): N/A
B: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Roflumilast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent) or Travoprost Ophthalmic Solution 0.004%
Brief Summary: Evaluation of the intraocular pressure (IOP) lowering effect of two iStent devices versus medical therapy in eyes of subjects with primary open-angle glaucoma, pseudoexfoliative glaucoma, or ocular hypertension naïve to medical and surgical therapy.


Options:
A: Arm Label: iStent; Type: ACTIVE_COMPARATOR; Interventions: Device: iStent | Arm Label: Drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Travoprost | Intervention Type: DEVICE; Name: iStent; Assigned to Arm(s): iStent | Intervention Type: DRUG; Name: Travoprost; Assigned to Arm(s): Drug
B: Arm Label: A--iStent plus Cataract Surgery; Type: ACTIVE_COMPARATOR; Interventions: Device: iStent plus Cataract Surgery | Arm Label: B--Cataract Surgery Only; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cataract surgery only | Intervention Type: DEVICE; Name: iStent plus Cataract Surgery; Assigned to Arm(s): A--iStent plus Cataract Surgery | Intervention Type: PROCEDURE; Name: Cataract surgery only; Assigned to Arm(s): B--Cataract Surgery Only
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Glaucoma Surgery | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Procedure: cataract surgery only | Intervention Type: DEVICE; Name: Glaucoma Surgery; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: cataract surgery only; Assigned to Arm(s): 2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: phacoemulsification alone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: iStent Trabecular Micro-Bypass Stent | Intervention Type: PROCEDURE; Name: phacoemulsification alone; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: iStent Trabecular Micro-Bypass Stent; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 26-Week Phase II, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Varenicline in Combination With Nicotine Replacement Therapy for Smoking Cessation
Brief Summary: The purpose of this study is to test whether the addition of a nicotine patch to varenicline increases smoking cessation success rate and whether the combination is safe.


Options:
A: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Augmented Treatment; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Behavioral: Behavioral Counseling Sessions, Drug: NicodermCQ | Arm Label: Standard Treatment w/ placebo; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Counseling Sessions, Drug: NicodermCQ, Drug: Placebo | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Augmented Treatment | Intervention Type: BEHAVIORAL; Name: Behavioral Counseling Sessions; Assigned to Arm(s): Augmented Treatment, Standard Treatment w/ placebo | Intervention Type: DRUG; Name: NicodermCQ; Assigned to Arm(s): Augmented Treatment, Standard Treatment w/ placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Standard Treatment w/ placebo
C: Arm Label: Varenicline and Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline and Placebo Patch | Arm Label: Varenicline and Nicotine Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Nicotine Patch | Intervention Type: DRUG; Name: Varenicline, Nicotine Patch; Assigned to Arm(s): Varenicline and Nicotine Patch | Intervention Type: DRUG; Name: Varenicline and Placebo Patch; Assigned to Arm(s): Varenicline and Placebo Patch
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 26-Week Phase II, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Varenicline in Combination With Nicotine Replacement Therapy for Smoking Cessation
Brief Summary: The purpose of this study is to test whether the addition of a nicotine patch to varenicline increases smoking cessation success rate and whether the combination is safe.


Options:
A: Arm Label: EGO/CE4, 9mg nicotine; Type: OTHER; Interventions: Device: EGO/CE4, 9mg nicotine | Intervention Type: DEVICE; Name: EGO/CE4, 9mg nicotine; Assigned to Arm(s): EGO/CE4, 9mg nicotine
B: Arm Label: Varenicline and Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline and Placebo Patch | Arm Label: Varenicline and Nicotine Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Nicotine Patch | Intervention Type: DRUG; Name: Varenicline, Nicotine Patch; Assigned to Arm(s): Varenicline and Nicotine Patch | Intervention Type: DRUG; Name: Varenicline and Placebo Patch; Assigned to Arm(s): Varenicline and Placebo Patch
C: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm III; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Arm III | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline(Chantix) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline(Chantix); Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B